Low-Dose Ketamine-Induced Deficits in Arbitrary Visuomotor Mapping in Monkeys

eNeuro. 2023 Jun 27;10(6):ENEURO.0015-23.2023. doi: 10.1523/ENEURO.0015-23.2023. Print 2023 Jun.

Abstract

Ketamine, an NMDA antagonist, is widely used in clinical settings. Recently, low-dose ketamine has gained attention because of its promising role as a rapid antidepressant. However, the effects of low-dose ketamine on brain function, particularly higher cognitive functions of primate brains, are not fully understood. In this study, we used two macaques as subjects and found that acute low-dose ketamine administration significantly impaired the ability for arbitrary visuomotor mapping (AVM), a form of associative learning (AL) essential for flexible behaviors, including executions of learned stimuli-response contingency or learning of new contingencies. We conducted in-depth analyses and identified intrinsic characteristics of these ketamine-induced functional deficits, including lowered accuracy, prolonged time for planning and movement execution, increased tendency to make errors when visual cues are changed from trial to trial, and stronger impact on combining associative learning and another key higher cognitive function, working memory (WM). Our results shed new light on how associative learning relies on the NMDA-mediated synaptic transmission of the brain and contribute to a better understanding of the potential acute side effects of low-dose ketamine on cognition, which can help facilitate its safe usage in medical practice.

Keywords: abstract rule; acute; cognition; ketamine; low-dose; visuomotor mapping.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain
  • Haplorhini
  • Ketamine* / toxicity
  • Memory, Short-Term
  • N-Methylaspartate / pharmacology

Substances

  • Ketamine
  • N-Methylaspartate